Aparna Nallagangula
Medical Oncology · Tucson, AZNPI 1093177875
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $241 of the $321 with a category attached, or 75.1%. 5 manufacturers reported payments, led by Galvanize Therapeutics, Inc at 38.1% of the total. 2024 is the largest year on record at $122, 5.2 times the $24 reported in 2019. That places this record below the midpoint for medical oncology clinicians in AZ, where the typical reported total is $8,518.
Across 7 payments — averaging $45.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galvanize Therapeutics, Inc$122
- Seagen Inc.$80
- Bristol Myers Squibb$71
- AstraZeneca$25
- Gilead$22
Across 78 payments — averaging $3890.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$160K
- E.r. Squibb & Sons, L.L.C.$111K
- Biontech SE$30K
- Modernatx, Inc.$2K
- Organon$750
What the payments were for
- Food & beverage$24175%
- Education$8025%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galvanize Therapeutics, Inc | 1 | $122 |
| Seagen Inc. | 1 | $80 |
| Bristol Myers Squibb | 3 | $71 |
| AstraZeneca | 1 | $25 |
| Gilead | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALIYA SYSTEM$122
How this compares
$321 in reported general payments places this provider in the 15th percentile of 59 medical oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocortisone | 49 | $1,463 |
| Levothyroxine Sodium | 47 | $446 |
| Prednisone | 43 | $174 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Tucson
- Michael BookmanTucson$46K
- Delmer Montoya MotinoTucson$26K
- Gerald HaginTucson$1K
- Leona DowneyTucson$50
- Morris FineTucson$35
- Jason SalganickPhoenix$1.6M
- Roopesh KantalaMesa$491K
- Nazish AhmadGlendale$205K
- Daniel von HoffScottsdale$165K
- David KahnSurprise$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.